Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is at the forefront of the discovery and clinical development of pioneering medicines targeting severe, rare diseases. Leveraging unique insights into physiocrine biology, a newly identified group of physiological modulators, aTyr aims to deliver breakthrough treatments to patients in need.
The company's flagship candidate, resolaris™, is a first-in-class intravenous protein therapeutic designed to address rare myopathies with an immune component. Resolaris™ is undergoing a series of Phase 1b/2 clinical trials, including trials for adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb girdle muscular dystrophy (LGMD) 2B or FSHD, and patients with an early onset form of FSHD.
aTyr Pharma holds a substantial intellectual property portfolio, featuring 70 issued or allowed patents and over 240 pending patent applications, all of which are solely owned or exclusively licensed by the company. This robust IP estate underpins their strategic focus on severe, rare diseases characterized by immune dysregulation.
One of the company’s notable recent achievements includes the development of efzofitimod, a first-in-class NRP2-targeting immunomodulator. Preclinical models have demonstrated that efzofitimod has significant immune regulatory functions, improving disease outcomes and mitigating fibrosis, particularly in rheumatoid arthritis and associated lung fibrosis.
In addition to its innovative drug pipeline, aTyr Pharma has bolstered its leadership and expertise by enlisting Dr. Frederick to guide corporate affairs and commercial strategies for efzofitimod in interstitial lung disease (ILD).
For the most current updates and detailed information, investors can contact Ashlee Dunston, Director of Investor Relations and Public Affairs, at adunston@atyrpharma.com.
aTyr Pharma, Inc. (Nasdaq: LIFE) has announced the initiation of two new discovery programs from its tRNA synthetase platform, focusing on Alanyl-tRNA Synthetase (AARS) and Aspartyl-tRNA Synthetase (DARS) fragments in immunology, fibrosis, and cancer. This effort aims to explore how these fragments affect natural killer (NK) cell biology, potentially leading to innovative therapies. The announcement follows a successful poster presentation at the SLAS 2021 conference, showcasing the interaction of these fragments with immune cells. aTyr’s current pipeline includes ATYR1923, targeting the Neuropilin-2 receptor.
aTyr Pharma (Nasdaq: LIFE) will present a corporate overview at the BIO CEO & Investor Digital Conference from February 16-18, 2021. Dr. Sanjay S. Shukla, President and CEO, will lead the presentation, available on-demand for attendees. A replay will be accessible on the company's website for 30 days post-event. In addition, management will hold virtual one-on-one meetings during the conference, which can be arranged through the partnering system or via email. aTyr focuses on innovative therapies targeting the extracellular functions of tRNA synthetases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the presentation of preclinical findings at the Virtual Keystone Symposia regarding Neuropilin-2 (NRP2) expression on immune cells in the tumor microenvironment. The poster highlights NRP2's significant role in cancer progression, particularly through its high expression in myeloid derived suppressor cells and tumor-associated macrophages. The findings may support the development of NRP2-targeted cancer therapeutics, including aTyr's lead antibody, ATYR2810. The live Q&A will be held on January 27, 2021.
SAN DIEGO, Jan. 22, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma (Nasdaq: LIFE) announced its participation in the virtual Society for Laboratory Automation and Screening Digital International Conference from January 25-27, 2021. The company will present a poster detailing a mass spectrometry proteomics method that identifies receptor targets for tRNA synthetase fragments AARS and DARS. Findings suggest potential applications in immunology, cancer, and fibrosis, supporting aTyr’s innovative biology platform and drug development efforts.
aTyr Pharma announced that its partner Kyorin Pharmaceutical has completed the final subject visit in the Phase 1 clinical trial of ATYR1923, triggering a milestone payment to aTyr. The trial evaluated safety and pharmacokinetics in 32 healthy Japanese male volunteers and aims to initiate patient trials for interstitial lung disease in Japan. Kyorin's progress with ATYR1923 is encouraging for aTyr, which is also conducting a Phase 1b/2a trial for pulmonary sarcoidosis and has previously tested ATYR1923 in COVID-19 patients.
aTyr Pharma (Nasdaq: LIFE) has announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM ET and will be accessible on the company's website for 90 days post-event. Additionally, the company will engage in virtual one-on-one meetings during the J.P. Morgan Healthcare Conference week (January 11-15, 2021), facilitated by the Biotechnology Innovation Organization.
aTyr Pharma announced positive topline results from its Phase 2 trial of ATYR1923 in hospitalized COVID-19 patients. The study met its primary safety endpoint with ATYR1923 being well-tolerated at doses of 1.0 and 3.0 mg/kg. Notably, patients receiving the 3.0 mg/kg dose demonstrated a median recovery time of 5.5 days, and 83% recovered in less than a week. The trial involved 32 patients and assessed safety and preliminary efficacy against a placebo. The company plans to provide further insights during a conference call on January 4.
aTyr Pharma (Nasdaq: LIFE) has announced the completion of target enrollment in its Phase 1b/2a clinical trial for ATYR1923, aimed at treating pulmonary sarcoidosis, with 36 patients enrolled. Results are anticipated in Q3 2021, potentially guiding future studies in interstitial lung diseases (ILD). ATYR1923 targets immune modulation to improve lung function with reduced toxicity compared to existing treatments. Additionally, a Phase 2 trial for COVID-19 patients has completed enrollment, with topline data expected soon.
aTyr Pharma has completed enrollment in its Phase 2 trial of ATYR1923 for COVID-19 patients, expecting topline data soon. The company is advancing its oncology pipeline with the new candidate ATYR2810 and has ongoing collaborations for research development. Financially, aTyr reported revenues of $0.1 million for Q3 2020, compared to $0.2 million in Q3 2019. R&D expenses rose to $4.6 million, reflecting increased clinical activities. As of September 30, 2020, cash and investments totaled $36.1 million, following the repayment of $3.1 million in loans.
On November 11, 2020, aTyr Pharma (Nasdaq: LIFE) announced a publication of a peer-reviewed paper demonstrating advancements in its antibody program. The research, conducted in collaboration with AbCellera Biologics, highlights methods for isolating and engineering human antibodies with high target affinity. Utilizing its tRNA synthetase biology platform, aTyr aims to create new biologics to modulate therapeutic pathways. The findings have already contributed to the development of antibody candidates for targeting Neuropilin-2, enhancing aTyr's pipeline for future therapeutic applications.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What does aTyr Pharma, Inc. specialize in?
What is aTyr Pharma's leading drug candidate?
In which clinical trial phases is resolaris™ currently?
What is the significance of physiocrine biology for aTyr Pharma?
How strong is aTyr Pharma's intellectual property portfolio?
What is efzofitimod?
Who can investors contact for more information?
What recent strategic addition did aTyr Pharma make?
When will aTyr Pharma's ticker symbol change take effect?
What is the focus of aTyr Pharma's key programs?
